Esperion Therapeutics, Inc. Annual Report - A 2025 Performance Snapshot

For investors tracking the pharmaceutical sector, Esperion Therapeutics (ESPR on NASDAQ) offers a compelling story. This summary provides key insights into the company's performance for the fiscal year ended December 31, 2025, focusing on its mission to develop and commercialize innovative therapies for cardiovascular and metabolic diseases.

1. Business Overview

Esperion Therapeutics develops and commercializes non-statin, oral medicines for patients with elevated LDL-C (often called "bad cholesterol"). Its flagship commercial products, NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), address a significant unmet need in cardiovascular health. The company strategically targets patient populations underserved by existing therapies, especially those who cannot tolerate statins or require additional lipid-lowering treatment.

2. Financial Performance

Esperion reported total revenue of $125 million for fiscal year 2025, marking a 20% increase from $104 million in 2024. This growth stemmed primarily from increased adoption of its key products. Product revenue, largely from NEXLETOL® and NEXLIZET®, reached $85 million, reflecting a 25% year-over-year increase due to expanded market access and physician prescribing. Collaboration revenue contributed $40 million, mainly from milestone payments and royalties from partners like Daiichi Sankyo Europe.

Despite robust revenue growth, the company recorded a net loss of $150 million in 2025. This represented an improvement from the $180 million net loss in 2024. Esperion reduced its loss through revenue growth and disciplined cost management, even while continuing significant investments in research and development (R&D) and commercialization efforts. Gross margin on product sales also improved, rising to 75% from 70% in the prior year.

3. Risk Factors

Esperion faces several significant risks that could materially affect its business, financial condition, and operational results:

• Product Concentration: Approximately 80% of product revenue comes from the NEXLETOL®/NEXLIZET® franchise. Any adverse events, new competitive entrants, market shifts, or changes in reimbursement policies impacting these products could severely affect financial performance.
• Customer Concentration: The company relies on a limited number of large pharmaceutical distributors for a significant portion of its U.S. sales. The top three distributors account for approximately 65% of gross product sales. Losing any of these distributors, or a significant reduction in their purchases, could harm the company's financial results.
• Clinical Development and Regulatory Hurdles: The success of pipeline candidates remains uncertain, and regulatory approvals are not guaranteed. Failure in clinical trials, delays in regulatory processes, or an inability to obtain necessary approvals could impact future growth and profitability.
• Competition: The cardiovascular and metabolic disease market is highly competitive. Esperion's products compete with established statins, other non-statin oral drugs (e.g., ezetimibe), PCSK9 inhibitors, and other investigational therapies, potentially limiting market share and pricing flexibility.
• Intellectual Property: Protecting its intellectual property is crucial. Loss of patent protection, successful challenges to its patents, or an inability to obtain new patents could lead to generic competition and significantly reduce revenue.
• Reliance on Collaborations: Esperion depends on partners for international commercialization and certain development activities. Their performance, strategic decisions, or financial stability can directly impact Esperion's revenue and strategic goals.
• R&D Costs: High research and development expenses continue to impact profitability as the company invests in its pipeline, which may not always yield successful commercial products.
• Supply Chain Volatility: The company may experience disruptions in the supply chain for raw materials or finished products, potentially affecting product availability and sales.

4. Management Discussion & Analysis (MD&A) Highlights

In 2025, Esperion demonstrated solid operational progress and strategic execution.

Achievements:

• Expanded Market Access: Esperion, through its partnership with Daiichi Sankyo Europe, successfully secured favorable reimbursement decisions in several key European markets, boosting international sales and collaboration revenue.
• Clinical Progress: The company announced positive topline data from a Phase 2 study for a new pipeline candidate in a related metabolic indication. This paves the way for potential Phase 3 trials in late 2026, signaling progress in pipeline diversification.
• Strategic Collaborations: Esperion strengthened existing partnerships with Otsuka Pharmaceutical (Japan), Neopharm (Israel), Seqirus (Australia/New Zealand), and HLS Therapeutics (Canada), expanding its geographic reach and diversifying revenue streams.

Challenges:

• Intense Competition: Esperion faced continued competitive pressure from existing lipid-lowering therapies and emerging treatments, requiring ongoing investment in commercial strategies to maintain and grow market share.
• R&D Investment: High research and development expenses remained a significant factor impacting profitability, reflecting the company's commitment to pipeline advancement despite ongoing net losses.
• Supply Chain Volatility: The company experienced minor disruptions in the supply chain for certain raw materials. However, effective operational management largely mitigated these issues without significantly impacting product availability.

Leadership and Strategy Changes: In Q3 2025, Esperion appointed a new Chief Commercial Officer. This appointment signals a renewed focus on optimizing commercial strategies and expanding market penetration for its existing products. The company's overall strategic direction continues to center on maximizing the value of the NEXLETOL®/NEXLIZET® franchise, advancing its pipeline, and exploring strategic partnerships to diversify its therapeutic areas and accelerate growth.

Market Trends and Regulatory Environment: Esperion operates within a dynamic healthcare landscape. Key trends include an increasing global prevalence of cardiovascular diseases, a growing emphasis on preventative care, and a demand for personalized medicine approaches. Regulatory changes, particularly regarding drug pricing and market access policies in major economies, continue to present both opportunities and challenges. The increasing focus on real-world evidence and value-based care models also influences Esperion's commercial strategies and clinical development plans.

5. Financial Health

As of December 31, 2025, Esperion held $220 million in cash and cash equivalents, including investments in money market funds and certificates of deposit. This provides an estimated cash runway of approximately 24 months based on current spending rates, indicating a solid liquidity position for ongoing operations and investments.

The company's debt structure includes convertible senior notes. Esperion largely converted or repaid the $120 million in convertible senior notes due in 2025 during the year, significantly reducing immediate debt obligations and improving the balance sheet. However, $200 million in convertible senior notes due in 2030 remain outstanding, representing a longer-term debt commitment. The company also maintains a $75 million credit agreement facility, of which $25 million was drawn as of year-end to support working capital needs, providing additional financial flexibility.

Esperion actively managed its capital through an "at-the-market" (ATM) program, raising approximately $50 million by selling shares directly into the market throughout 2025. It also completed a $30 million commitment offering to institutional investors, further bolstering its cash position and liquidity. These actions demonstrate proactive capital management to support operations and strategic initiatives.

6. Future Outlook

Esperion projects continued revenue growth in 2026, driven by further market penetration of its commercial products and potential milestone payments from international partners. The company anticipates a significant subsequent event in early 2026 related to Corstasis Therapeutics Inc. This event is expected to be a strategic acquisition or partnership aimed at expanding Esperion's pipeline into a complementary cardiovascular or metabolic indication, potentially adding a late-stage asset. Management focuses on achieving profitability within the next 2-3 years through continued revenue growth and stringent cost control, outlining a clear path towards sustainable financial performance.

7. Competitive Position

Esperion operates in a highly competitive global market for lipid-lowering therapies. Its primary products, NEXLETOL® and NEXLIZET®, offer a differentiated non-statin oral option for patients who cannot tolerate statins or require additional LDL-C lowering. They compete with established statin therapies, other non-statin oral drugs (e.g., ezetimibe), injectable PCSK9 inhibitors, and emerging therapies. Esperion's competitive advantage lies in its oral formulation, targeted mechanism of action (ATP Citrate Lyase inhibition), and strong clinical data supporting cardiovascular risk reduction in specific patient populations. The company aims to solidify its position as a leader in non-statin oral therapies for high-risk cardiovascular patients.